A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

NCT03740724 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Morphea
Scleroderma, Localized
Scleroderma

Interventions

GENETIC: FCX-013
DRUG: veledimex

Sponsor

Castle Creek Biosciences, LLC.